Clinical & Translational Oncology最新文献

{"title":"Management of glioblastoma in the elderly.","authors":"Idoia Morilla, Edinson Caviedes, Regina Gironés Sarrió, Borja López de San Vicente Hernández, Natalia Luque Caro, Sonia Del Barco, Juana M Cano, María Ángeles Vaz-Salgado","doi":"10.1007/s12094-026-04546-8","DOIUrl":"https://doi.org/10.1007/s12094-026-04546-8","url":null,"abstract":"<p><p>Glioblastoma is the most aggressive and common malignant primary brain tumor among adults. Due to its aggressiveness, GBM entails a short median overall survival and fatal outcomes. Incidence notably increases with age, 50% of patients being diagnosed at the age of 65 or older. Given that cognitive loss is commonly confused with age-related cognitive impairment, delays in diagnosis are frequent. Furthermore, the elderly are a vulnerable group, commonly having poorer functional status, more comorbidities, and reduced tolerance to intensive treatments. Therefore, clinical and therapeutic implications should be considered within a multidisciplinary approach. The aim of the present study was to review the current knowledge on the management of glioblastoma in the elderly population (≥ 65 years).</p>","PeriodicalId":50685,"journal":{"name":"Clinical & Translational Oncology","volume":" ","pages":""},"PeriodicalIF":2.7,"publicationDate":"2026-09-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148892838","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Prognostic modeling of overall survival in metastatic pancreatic cancer: an inflammation-based tool validated in PANTHEIA-SEOM cohort.","authors":"Vilma Pacheco-Barcia, Axel Mariño-Mendez, María Ángeles Vicente Conesa, María de Toro Carmena, Paula Cerdà Serdà, Carmen Guillen-Ponce, Mónica Benavente Lucas, Raquel Hernández San Gil, Ángela Lamarca, Javier Gallego, Maria Luisa Soriano Tabares de Nava, Jorge Hernando, Elena Brozos-Vazquez, Ana López-Alfonso, Jorge Adeva, Ismael Ghanem, Sandra Soriano, Javier Soto-Alsar, Andrés Muñoz, Paula Jimenez-Fonseca, Alberto Carmona-Bayonas","doi":"10.1007/s12094-026-04554-8","DOIUrl":"https://doi.org/10.1007/s12094-026-04554-8","url":null,"abstract":"<p><strong>Purpose: </strong>To develop and internally validate the PANTHEIA-SIRI prognostic model, which integrates log-transformed systemic inflammation response index (SIRI) with clinical predictors, to estimate overall survival (OS) in metastatic pancreatic ductal adenocarcinoma (mPDAC) treated with first-line chemotherapy.</p><p><strong>Methods: </strong>We used data from the multicenter PANTHEIA-SEOM registry. OS was defined from chemotherapy start. The model was fitted as a Weibull accelerated failure time model in the survival-analysis population with multiple imputation. Predictors were log-transformed baseline SIRI, modeled with restricted cubic splines, ECOG, tumor burden, chemotherapy regimen, and anorexia-cachexia syndrome. Internal validation used a separate, non-overlapping cohort from the same registry; the centers contributing to each cohort are listed in a supplementary annex. TRIPOD was followed. Discrimination was assessed with Harrell´s C-index and calibration with IPCW Brier scores and IPA.</p><p><strong>Results: </strong>The derivation cohort comprised 672 patients with SIRI data (593 analyzed for survival) across 22 Spanish hospitals (2015-2025); 80.1% had died after a median OS of 9.9 months. The imputation-pooled derivation C-index was 0.654 (95% CI, 0.627-0.681); optimism-corrected, 0.629. Internal validation used 62 separate patients from the same registry; 96.8% had died after a median OS of 9.2 months. The validation C-index was 0.603 (95% CI, 0.518-0.687). Calibration was adequate at 6 and 12 months.</p><p><strong>Conclusions: </strong>The PANTHEIA-SIRI model provides individualized OS estimates in mPDAC with routine clinical predictors. Its open-access calculator ( https://pantheia-siri.shinyapps.io/calc/ ) may support prognostic communication, treatment-intensity selection, and supportive-care planning. Routine clinical implementation will require further validation in larger, fully independent cohorts.</p>","PeriodicalId":50685,"journal":{"name":"Clinical & Translational Oncology","volume":" ","pages":""},"PeriodicalIF":2.7,"publicationDate":"2026-09-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148889295","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Recommendations from the Spanish Society of Medical Oncology to advance the humanization in cancer care.","authors":"Sergio Vázquez, Tamara Fenollosa Sanz, M Helena Huertas, Julio Lambea, Ana López-González, Braulio Martín, Álvaro Romanos Nanclares, Cristina Sánchez, Miguel Ángel Seguí, Lucía Teijeira Sánchez, Jesús Corral, Isabela Díaz de Corcuera","doi":"10.1007/s12094-026-04513-3","DOIUrl":"https://doi.org/10.1007/s12094-026-04513-3","url":null,"abstract":"<p><p>Humanization in cancer care is increasingly recognized as a core component of healthcare quality, yet its implementation in clinical practice remains uneven. To address this gap, the Spanish Society of Medical Oncology (SEOM) developed a humanization protocol to guide its integration into routine oncology care. Based on a review of scientific literature, including clinical guidelines and documents from scientific societies, together with a SEOM survey of medical oncologists, the recommendations are organized around four domains: people, processes, spaces, and society. For each domain, practical and adaptable measures are proposed, ranging from communication and shared decision-making to care coordination, the design of healthcare environments, professional well-being, and community engagement. A cross-cutting person-centered approach, combined with regular evaluation using patient-experience and professional well-being indicators, may support the integration of humanization into routine cancer care.</p>","PeriodicalId":50685,"journal":{"name":"Clinical & Translational Oncology","volume":" ","pages":""},"PeriodicalIF":2.7,"publicationDate":"2026-09-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148889306","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Clinical outcomes of stereotactic body radiotherapy in oligometastatic disease: a national real-world cohort study.","authors":"Macarena Teja, Fernando López Campos, Álvaro Pinto, Israel J Thuissard, María González, David Esteban, Abrahams Ocanto, Castalia Fernández, Daniela Gonsalves, Lisselott Torres, María Isabel Garrido, Escarlata López, Jaume Fernández, Loubna Aakki, Antonio Ristori, José Begara, Sigfredo Elias Romero Zoghbi, Jon Andreescu, Ana Belén Bezares, María Mateos, Miguel Ángel Berenguer, Daniel Rivas, Elisabet González Del Portillo, Cristina Andreu, Esther Holgado, Shankar Siva, Constantinos Zamboglou, Felipe Couñago","doi":"10.1007/s12094-026-04557-5","DOIUrl":"https://doi.org/10.1007/s12094-026-04557-5","url":null,"abstract":"<p><strong>Purpose: </strong>We conducted the first multicentre Spanish real-world study assessing the efficacy and safety of stereotactic body radiotherapy (SBRT) in oligometastatic patients treated in routine clinical practice.</p><p><strong>Methods: </strong>This retrospective, multicentre observational study included oligometastatic patients with primary solid tumours treated with SBRT between 2020 and 2024 across 12 Spanish radiotherapy centres. The primary endpoint was 1-year progression-free survival (PFS). The secondary endpoints included overall survival (OS), local control (LC), and acute and late adverse events by CTCAE v.5.0.</p><p><strong>Results: </strong>300 patients with 451 treated lesions were included. Median age was 69 years. After a median follow-up of 22 months, 1- and 2-year PFS were 45.1% and 36.3% respectively, with a median PFS of 11 months (95% CI, 9-13). The 1- and 2-year OS were 92% and 82.9% (median not reached), and 1- and 2-year LC were 90.5% and 85.5% respectively. Multivariable analyses showed significantly better PFS and OS in prostate cancer patients. Repeat and induced oligometastatic patients showed worse PFS than those with synchronous disease (HR 2.86, 95% CI 1.59-5.13; p<0.001 and HR 2.97, 95% CI 1.58-5.57; p<0.001, respectively). Visceral-only disease also correlated with worse PFS compared to bone-only metastases. Local control was poorer in lesions ≥5 cm compared to <5 cm (p<0.001). Grade ≥3 acute and late adverse events occurred in 0.7% and 1% of patients.</p><p><strong>Conclusion: </strong>In this real-world multicentre cohort, SBRT to the oligometastases showed efficacy with minimal adverse events. Prognostic differences among subgroups underscore the importance of an adequate patient selection and individualized treatment strategies.</p>","PeriodicalId":50685,"journal":{"name":"Clinical & Translational Oncology","volume":" ","pages":""},"PeriodicalIF":2.7,"publicationDate":"2026-09-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148882141","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Exercise inhibits proliferation and induces apoptosis of lung adenocarcinoma cells via the POU2F2-SPOCD1-PI3K/AKT signaling axis.","authors":"Shujing Shi, Yumu Leng, Linfei Yang, Buyi Zhu, Haixin Tan, Fengming Wang, Jiaqi Pan, Zhenhua Yang, Wei Gu, Weiwei He","doi":"10.1007/s12094-026-04273-0","DOIUrl":"10.1007/s12094-026-04273-0","url":null,"abstract":"<p><strong>Background: </strong>Lung adenocarcinoma (LUAD) is a prevalent and deadly form of lung cancer. Exercise has been shown to inhibit LUAD progression, yet the underlying molecular mechanisms remain unclear. The transcription factor POU2F2 has been implicated in LUAD tumorigenesis, but its precise role and regulatory targets have not been fully elucidated.</p><p><strong>Methods: </strong>POU2F2 expression in LUAD cell lines (HCC4006, Calu-3, NCI-H2009) and normal lung epithelial cells (BEAS-2B) was assessed by qRT-PCR and Western blot. Functional assays (CCK-8, EdU, flow cytometry, TUNEL) were performed following shRNA-mediated knockdown of POU2F2 or SPOCD1 and upregulation of POU2F2. Mechanistic studies included bioinformatics, dual-luciferase assay, ChIP, DNA pull-down, and Western blot. In vivo tumor growth was evaluated via xenograft models with Ki67 IHC.</p><p><strong>Results: </strong>Exercise suppressed POU2F2 expression, which was otherwise elevated in LUAD cells. Knockdown of POU2F2 or its downstream target SPOCD1 reduced proliferation and increased apoptosis. Mechanistically, POU2F2 directly bound to and activated the SPOCD1 promoter, thereby enhancing PI3K/AKT pathway signaling. Rescue experiments confirmed that SPOCD1 mediates POU2F2's oncogenic effects. In vivo, POU2F2 knockdown inhibited tumor growth and Ki67 expression.</p><p><strong>Conclusions: </strong>Exercise suppresses LUAD progression by downregulating POU2F2, thereby disrupting the POU2F2-SPOCD1-PI3K/AKT axis. This pathway plays a critical role in LUAD cell survival and may serve as a promising therapeutic target.</p><p><strong>Key points: </strong>Exercise inhibits LUAD progression by downregulating the oncogenic transcription factor POU2F2. The POU2F2-SPOCD1 axis exerts its oncogenic function by activating the PI3K/AKT pathway. The POU2F2-SPOCD1 axis may represent a promising therapeutic target for LUAD.</p>","PeriodicalId":50685,"journal":{"name":"Clinical & Translational Oncology","volume":" ","pages":"3774-3789"},"PeriodicalIF":2.7,"publicationDate":"2026-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13499754/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147379475","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Utilization of MRI-based radiomics nomogram for predicting HER2-zero, -low, and -overexpression breast cancer.","authors":"Licui Zhang, Qinghong Duan, Ting Zhao, Jian He, Hongyang Li, Zhuoya Ma, Yong Wen, Ying Lei","doi":"10.1007/s12094-026-04232-9","DOIUrl":"10.1007/s12094-026-04232-9","url":null,"abstract":"<p><strong>Objective: </strong>This study sought to retrospectively investigate the clinical utility of a radiomics nomogram based on MRI for stratifying HER2 expression status in breast tumors into three categories.</p><p><strong>Materials and methods: </strong>This study recruited females from two centers who had a pathological confirmation of invasive breast cancer (BC) between January 2024 and March 2025. Based on the T2-weighted image (T2WI) and dynamic contrast-enhanced magnetic resonance imaging (DCE-MRI), radiomic features were extracted. Feature selection was subsequently performed by analysis of variance (ANOVA), Spearman's correlation analysis, the Wilcoxon test, and the least absolute shrinkage and selection operator (LASSO) method. Two classification tasks were determined: Task 1, differentiating HER2 overexpression (positive) from HER2-low/zero (negative) tumors and Task 2, distinguishing HER2-low from HER2-zero tumors. To pinpoint clinicopathological markers associated with the HER2 status, univariate and multivariate logistic regression analyses were carried out. Moreover, a nomogram, integrated by key MRI radiomics features, was crafted. Model efficacy was gauged using the receiver operating characteristic (ROC) curve, sensitivity, specificity, and accuracy. Clinica applicability was examined via decision curve analysis (DCA).</p><p><strong>Results: </strong>The integrated model incorporating T2WI and DCE-MRI features achieved better results than models using only one modality. In Task 1, the nomogram demonstrated good calibration and discrimination capabilities, with an area under the curve (AUC) of 0.82 and 0.80 in training and validation sets. For Task 2, the nomogram achieved an AUC of 0.88 (training) and 0.80 (validation).</p><p><strong>Conclusions: </strong>The radiomics nomogram provides a non-invasive choice for predicting HER2 expression in BC, which may assist in personalized treatment planning.</p>","PeriodicalId":50685,"journal":{"name":"Clinical & Translational Oncology","volume":" ","pages":"3850-3861"},"PeriodicalIF":2.7,"publicationDate":"2026-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147391676","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Prognostic ımpact of the modified Ryan tumor regression score in gastric and GEJ adenocarcinomas treated with neoadjuvant FLOT regimen.","authors":"Mehmet Akif Parlar, Burak Bilgin, Bülent Yalçın, Efnan Algın, Öznur Bal, Serhat Sekmek, Furkan Ceylan, Mehmet Ali Nahit Şendur","doi":"10.1007/s12094-026-04309-5","DOIUrl":"10.1007/s12094-026-04309-5","url":null,"abstract":"<p><strong>Objective: </strong>This study aimed to evaluate the prognostic significance of the Modified Ryan Tumor Regression Score (TRG) in predicting overall survival (OS) and disease-free survival (DFS) among patients with locally advanced gastric and gastroesophageal junction (GEJ) adenocarcinomas treated with neoadjuvant FLOT chemotherapy (5-fluorouracil, leucovorin, oxaliplatin, and docetaxel). We aimed to evaluate whether the modified Ryan TRG independently predicts DFS and OS in a homogeneous FLOT-treated cohort.</p><p><strong>Materials and methods: </strong>Patients with locally advanced gastric or GEJ adenocarcinomas who received neoadjuvant FLOT and underwent curative surgery were retrospectively reviewed. The Modified Ryan TRG was categorized into four grades (0-3) according to the proportion of residual viable tumor cells.</p><p><strong>Results: </strong>A total of 154 patients were included in the analysis. Among all patients, 26.6% achieved a good pathological response (TRG 0-1), 24.7% had a partial response (TRG 2), and 48.7% showed minimal or no response (TRG 3). Median DFS and OS were not reached in the TRG 0-1 group, whereas they were 16.1 and 29.9 months, respectively, in the TRG 3 group (p < 0.001). Lower TRG (0-1) independently predicted improved DFS (HR = 0.07, p < 0.001) and OS (HR = 0.10, p = 0.002).</p><p><strong>Conclusion: </strong>The Modified Ryan Tumor Regression Score represents a strong and independent prognostic indicator in patients with locally advanced gastric and GEJ adenocarcinomas treated with the FLOT regimen. Patients with low TRG (0-1) scores exhibit superior survival outcomes, while those with high TRG (3) scores may benefit from closer follow-up and intensified adjuvant strategies. Prospective studies are warranted to validate TRG-based individualized treatment approaches.</p>","PeriodicalId":50685,"journal":{"name":"Clinical & Translational Oncology","volume":" ","pages":"3931-3940"},"PeriodicalIF":2.7,"publicationDate":"2026-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147482328","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Recommendations for the development of an integrated lung cancer care process: an expert consensus report.","authors":"Margarita Majem, Patricia Alonso-Fernández, Pilar Garrido López, Ángel Gayete, Florentino Hernando, José Luis López-Guerra, Maria D Lozano, Bartomeu Massuti, Luis Paz-Ares, Santiago Ramón Y Cajal, Vanesa Rodríguez-Sales, Luis Seijo, Antoni Sisó-Almirall, David Vicente, Laureano Molins","doi":"10.1007/s12094-026-04275-y","DOIUrl":"10.1007/s12094-026-04275-y","url":null,"abstract":"<p><strong>Objective: </strong>To identify key aspects of the lung cancer care process and generate prioritised recommendations to optimise coordination, quality, and equitable access to diagnosis and treatment.</p><p><strong>Methods: </strong>24 experts from the National Advisory Committee of the Lung Ambition Alliance in Spain participated in a structured consensus process using an adapted RAND/UCLA method. The process comprised three phases: literature review (Phase I), identification of key issues (Phase II, n = 21), and prioritisation of recommendations (Phase III, n = 24). Each recommendation was scored for impact and feasibility on a 1-9 Likert scale. Agreement was defined when ≥ 66.6% of experts rated within the same range as the median; disagreement when ≥ 33.3% scored in both the 1-3 and 7-9 ranges; other cases were considered indeterminate.</p><p><strong>Results: </strong>A total of 76 recommendations addressing 34 key aspects were identified (66% related to humanisation and perceived care quality and 34% to coordination and continuity). From which, 62 achieved agreement for impact and 14 were indeterminate; regarding feasibility, 10 reached agreement, 2 met disagreement criteria and 64 were indeterminate. In this regard, 17 high-priority recommendations (high impact and feasibility) were prioritised, covering prevention, access to diagnosis and treatment, standardisation of care processes and communication with patients. In addition, 29 recommendations were classified as high impact, relating to information systems, care coordination, prevention and awareness, equity in access to diagnostic tests and treatment, and patient care and safety.</p><p><strong>Conclusions: </strong>Implementing these recommendations is essential to enhance equity, coordination, and quality of lung cancer care, requiring a nationwide, multi-stakeholder effort to advance towards an integrated and patient-centred model.</p>","PeriodicalId":50685,"journal":{"name":"Clinical & Translational Oncology","volume":" ","pages":"3803-3816"},"PeriodicalIF":2.7,"publicationDate":"2026-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13499717/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147476159","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Clinical experience and satisfaction in patients with advanced breast cancer participating in the abemaciclib patient support program in Spain: a prospective observational study.","authors":"Isabel Blancas, Miriam González de la Peña, María Fernández Abad, Silvia Antolín Novoa, Encarna Adrover Cebrián, Rodrigo Sánchez Bayona, Esther Zamora Adelantado, Raquel Andrés Conejero, Sonia Del Barco Berrón, Manuel Atienza, Alberto Molero, Silvia Díaz-Cerezo, Clara Pérez-Rambla, F J Pérez-Sádaba, Luis Manso","doi":"10.1007/s12094-026-04267-y","DOIUrl":"10.1007/s12094-026-04267-y","url":null,"abstract":"<p><strong>Purpose: </strong>To evaluate the impact of a patient support program (PSP) on the management of abemaciclib-related diarrhea in patients with hormone receptor-positive, human epidermal growth factor receptor 2-negative (HR+/HER2-) metastatic breast cancer (MBC) and its influence on adherence and patient-reported outcomes in routine clinical practice.</p><p><strong>Methods: </strong>This is a multicenter, prospective, observational Spanish study in patients with locally advanced or MBC receiving abemaciclib and enrolled in the PSP, assessed over 6 months. The primary endpoint was the proportion of patients reducing or discontinuing abemaciclib due to diarrhea. The secondary endpoints included diarrhea-related temporary interruptions, diarrhea management, adherence, HRQoL, and satisfaction with the PSP. Descriptive statistics were applied and treatment modification endpoints were analyzed using Kaplan-Meier.</p><p><strong>Results: </strong>The study included 39 patients (median age: 58 years), with a median time since diagnosis of MBC of 2 months. Diarrhea occurred in 89.7% of patients, with grade 3 events in 7.7% and no grade ≥ 4 events. Nine patients (23.1%) experienced treatment modifications due to diarrhea; however, no permanent treatment discontinuations were reported. Loperamide (over 75% of patients) and dietary modifications were the most used self-care strategies. At week 24, results from the ad hoc questionnaires showed that over 70% of the patients reported high satisfaction with all PSP aspects, and 80% were classified as treatment adherent.</p><p><strong>Conclusions: </strong>Episodes of diarrhea were mostly graded 1-2 and no patients discontinued abemaciclib due to diarrhea. Patients reported high satisfaction with abemaciclib PSP, good adherence, and favorable quality of life, supporting the use of PSP in clinical practice.</p>","PeriodicalId":50685,"journal":{"name":"Clinical & Translational Oncology","volume":" ","pages":"3862-3871"},"PeriodicalIF":2.7,"publicationDate":"2026-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13499750/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147445771","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"FAT4 loss promotes tumor growth and ferroptosis resistance in hepatocellular carcinoma via PI3K/AKT pathway activation.","authors":"Jing Li, Jialing Sun, Rui Hu, Mengqing Ma, Kongli Fan, Minling Lv, Qi Huang, Wenmin Yang, Yuan Yang, Yan Wang, Xiaozhou Zhou, Xinfeng Sun","doi":"10.1007/s12094-026-04302-y","DOIUrl":"10.1007/s12094-026-04302-y","url":null,"abstract":"<p><strong>Purpose: </strong>Drug resistance in hepatocellular carcinoma (HCC) presents a substantial therapeutic challenge. Ferroptosis has emerged as a promising therapeutic strategy, yet the mechanisms underlying resistance are not fully elucidated. Here, we highlight the tumor suppressor FAT4 as a crucial regulator of ferroptosis sensitivity in HCC.</p><p><strong>Methods: </strong>We examined the role of FAT4 in ferroptosis in HCC using a combination of bioinformatics analysis, experiments on tissue samples from patients with HCC, and a subcutaneous xenograft tumor model in nude mice.</p><p><strong>Results: </strong>FAT4 expression was significantly downregulated in HCC tissues, and this downregulation correlated with poor patient survival. Functionally, FAT4 loss promoted tumor growth and resistance to ferroptosis inducers (RSL3 and sorafenib), evidenced by reduced lipid peroxidation and increased levels of GPX4 and SLC7A11. Mechanistically, FAT4 deficiency was associated with activation of the PI3K/AKT signaling pathway. Notably, pharmacological inhibition of PI3K/AKT restored ferroptosis sensitivity and resensitized FAT4-deficient HCC cells to sorafenib.</p><p><strong>Conclusions: </strong>FAT4 may enhance ferroptosis sensitivity in HCC by suppressing GPX4 and SLC7A11 expression, potentially by inhibiting PI3K/AKT signaling. Thus, this study presents FAT4 as a biomarker associated with tumor progression and a potential determinant for overcoming ferroptosis resistance in HCC.</p>","PeriodicalId":50685,"journal":{"name":"Clinical & Translational Oncology","volume":" ","pages":"3973-3991"},"PeriodicalIF":2.7,"publicationDate":"2026-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147459790","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}